Literature DB >> 34125289

Treatment outcomes in the neovascular glaucoma tube versus trabeculectomy study.

Kana Tokumo1, Kaori Komatsu2, Yuki Yuasa2, Yumiko Murakami2, Hideaki Okumichi2, Kazuyuki Hirooka2, Shunsuke Nakakura3, Hitoshi Tabuchi3, Yoshiaki Kiuchi2.   

Abstract

PURPOSE: To compare surgical outcomes between patients who underwent Baerveldt glaucoma implantation versus trabeculectomy (TLE) for the treatment of neovascular glaucoma.
METHODS: We performed a prospective, randomized, controlled clinical trial at Hiroshima University and Tsukazaki Hospital, Japan. Patients were randomized to Baerveldt glaucoma implantation (23 patients) or TLE (27 patients). The primary outcome measure was the rate of intraocular-pressure control. Secondary outcome measures included complications and interventions. We defined "failure" as intraocular pressure ≥ 22 mmHg or < 20% reduction from baseline pressure, on two consecutive follow-up visits; need for additional glaucoma surgery; vision-threatening complications; or loss of light perception. Kaplan-Meier analysis was used to determine surgical success rates. Postoperative complications and interventions were compared between the two groups with Pearson Chi-square tests.
RESULTS: There were no significant differences in demographic or ocular characteristics between the treatment groups at baseline. The postoperative follow-up was 26.6 ± 19.4 months in the Baerveldt group and 27.3 ± 20.1 months in the TLE group. There were no statistical differences (Mann-Whitney nonparametric tests with Bonferroni correction) in postoperative intraocular pressure measured at 6-month intervals. Success rates were 59.1 and 61.6% at 1-year after Baerveldt glaucoma implantation and TLE, respectively. Kaplan-Meier analysis showed no significant difference in success between groups (P = 0.71, log-rank test). Medication use, visual acuity, and interventions were similar between groups. Thirteen late postoperative complications developed in the Baerveldt glaucoma implantation group and four complications developed in the TLE group. Tube exposure was the most common late complication.
CONCLUSION: These two procedures produced similar surgical success, intraocular-pressure reductions, visual acuity, and number of medications at the last visit. The TLE group showed smaller numbers of late complications and patients who lost more than two lines of visual acuity. Therefore, TLE might be a safer and better way to treat patients with neovascular glaucoma.

Entities:  

Keywords:  Neovascular glaucoma; Randomized controlled clinical trial; Trabeculectomy; Tube-shunt surgery

Year:  2021        PMID: 34125289     DOI: 10.1007/s00417-021-05257-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  23 in total

1.  Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma.

Authors:  Yoshiaki Kiuchi; Kazuto Nakae; Yoshihiro Saito; Shigeo Ito; Nami Ito
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

2.  The Ahmed Baerveldt Comparison (ABC) Study: Long-Term Results, Successes, Failures, and Complications.

Authors:  Edward J Rockwood
Journal:  Am J Ophthalmol       Date:  2016-01-29       Impact factor: 5.258

3.  Using the early postoperative intraocular pressure to predict pressure control after a trabeculectomy.

Authors:  Satoshi Okimoto; Yoshiaki Kiuchi; Tomoyuki Akita; Junko Tanaka
Journal:  J Glaucoma       Date:  2014-08       Impact factor: 2.503

4.  Filtration surgery in the treatment of neovascular glaucoma.

Authors:  R C Allen; A R Bellows; B T Hutchinson; S D Murphy
Journal:  Ophthalmology       Date:  1982-10       Impact factor: 12.079

5.  Mid-term effects of trabeculectomy with mitomycin C in neovascular glaucoma patients.

Authors:  S M Hyung; S K Kim
Journal:  Korean J Ophthalmol       Date:  2001-12

Review 6.  Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.

Authors:  J A Sivak-Callcott; D M O'Day; J D Gass; J C Tsai
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

7.  The Ahmed Versus Baerveldt Study: Five-Year Treatment Outcomes.

Authors:  Panos G Christakis; Jeffrey W Kalenak; James C Tsai; David Zurakowski; Jeffrey A Kammer; Paul J Harasymowycz; Juan J Mura; Louis B Cantor; Iqbal I K Ahmed
Journal:  Ophthalmology       Date:  2016-08-17       Impact factor: 12.079

8.  Trabeculectomy with mitomycin C for neovascular glaucoma: prognostic factors for surgical failure.

Authors:  Yuji Takihara; Masaru Inatani; Mikiko Fukushima; Keiichiro Iwao; Minako Iwao; Hidenobu Tanihara
Journal:  Am J Ophthalmol       Date:  2009-02-05       Impact factor: 5.258

9.  Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications.

Authors:  Lan Liu; Yongfeng Xu; Zhu Huang; Xiaoyu Wang
Journal:  BMC Ophthalmol       Date:  2016-05-26       Impact factor: 2.209

10.  The Primary Tube Versus Trabeculectomy Study: Methodology of a Multicenter Randomized Clinical Trial Comparing Tube Shunt Surgery and Trabeculectomy with Mitomycin C.

Authors:  Steven J Gedde; Philip P Chen; Dale K Heuer; Kuldev Singh; Martha M Wright; William J Feuer; Joyce C Schiffman; Wei Shi
Journal:  Ophthalmology       Date:  2017-12-18       Impact factor: 14.277

View more
  2 in total

1.  The influence of etiology on surgical outcomes in neovascular glaucoma.

Authors:  Charles M Medert; Catherine Q Sun; Elizabeth Vanner; Richard K Parrish; Sarah R Wellik
Journal:  BMC Ophthalmol       Date:  2021-12-20       Impact factor: 2.209

2.  A systematic review and meta-analysis of randomised controlled trials in the management of neovascular glaucoma: absence of consensus and variability in practice.

Authors:  Saajan Ramji; Gurnoor Nagi; Abdus Samad Ansari; Obeda Kailani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-08       Impact factor: 3.535

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.